|Dr. Werner Lanthaler MBA, MPA||CEO & Member of Management Board||792k||N/A||49|
|Mr. Enno Spillner||CFO & Member of Management Board||158k||N/A||47|
|Dr. Mario Polywka Ph.D.||COO & Member of Management Board||614k||N/A||54|
|Dr. Cord Dohrmann Ph.D.||Chief Scientific Officer & Member of Management Board||501k||N/A||53|
|Katja Schrader||Chief Editor||N/A||N/A||N/A|
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of immunology and inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, Respiratory, and Immunology and Inflammation; EVT770 for diabetes type 2/1; and EVT801, EVT701, and EVT601 for oncology. The company has alliances and partnerships with AstraZeneca AB; Bayer Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; CHDI Foundation, Inc.; MedImmune; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Innovation; Novartis AG; Sanofi; ex scientia Ltd; Bayer AG; Pfizer; C4X Discovery Holdings plc; Asahi Kasei Pharma Corporation; STORM Therapeutics; and ABIVAX, as well as a research collaboration with Inserm Transfert SA and Center for Regenerative Therapies Dresden to discover novel therapies for retinal diseases. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Evotec AG’s ISS Governance QualityScore as of February 1, 2018 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 9.